SS-31 (Elamipretide) Deep Dive — Cardiolipin, FDA Approval, Off-Label Uses
Provenance: educational study-synthesis (secondary source)
SS-31 is the first FDA-approved peptide discussed in this base (for Barth syndrome) → it has far more human safety data than most. Off-label uses below are still mechanism/preclinical-based.
[educational]; research/educational use only. Source: YouTube — cjUm5gkSwRk (Thorough structured capture; full verbatim not stored.)
Identity & mechanism
SS-31 (elamipretide) is a mitochondrial-targeted synthetic tetrapeptide (4 aa, positively charged) — vs MOTS-C/humanin which are mitochondrial-derived. Its charge/structure let it penetrate to the inner mitochondrial membrane, where it binds and stabilizes cardiolipin (the negatively-charged phospholipid that holds the electron transport chain stable). Stable cardiolipin → stable ETC → more ATP, fewer reactive oxygen species → breaks the vicious cycle of mitochondrial dysfunction (a root cause of aging and many chronic diseases). It is structural support, not a signaling/growth molecule.
FDA approval + studied uses
- FDA-APPROVED for Barth syndrome (ultra-rare cardiolipin disorder): 168-week human trial → +30–40% muscle strength/function, ~50% improvement in heart-function markers. This is its only approved use; everything below is off-label.
- Off-label (mostly preclinical): dementia/cognitive decline (Alzheimer’s mouse — ↑learning/memory), TBI (mouse — less secondary brain damage), chronic kidney disease (multiple mouse models + a small human phase-2 in renal-artery stenting → improved kidney function/blood flow), diabetes/insulin resistance (mouse), chronic fatigue / long COVID (anecdotal + proven ATP increase), anti-aging/healthspan (mouse functional markers — exercise capacity, muscle/heart function, ↓frailty; cardiolipin declines with age).
Safety (notably strong)
Extensive human safety data, all SubQ 40 mg/day with only injection-site reactions, no significant AEs: Barth (168 wk), primary mitochondrial myopathy (218 pts, 24 wk), age-related macular degeneration (176 pts, 48 wk), heart failure (71 pts, 28 d). Mechanistically clean: no receptors/signaling/growth pathways → no cancer/immune-dysregulation concern, and no mitochondrial-overstress concern (unlike MOTS-C).
Forms, dose, frequency, cycles
- SubQ (IV also studied; no oral human/animal data — at 4 aa it’s too large for the 2–3-aa intestinal di/tripeptide transporters, so poor oral bioavailability without advanced formulation).
- Dose: human trials all 40 mg/day, but in extreme-dysfunction populations (Barth, myopathies). For age-related/normal mitochondria, less likely suffices; cost ~**40/day). Anti-aging mouse HEDs work out to ~5–17 mg/day → start 5–10 mg/day, titrate by 5 mg to a max of 40 mg, guided by symptoms + labs.
- Frequency: daily (cleared from plasma <24 h; structural role needs continuous exposure) — though it accumulates in mitochondria and may “reset” the dysfunction cycle, so less-frequent dosing might work (prefer daily 5–10 mg over 2×/wk).
- Cycles: trials ran continuously long-term; little tolerance/tachyphylaxis (no receptors). Cycle only for cost/unknown-safety; anti-aging starting point 1 month on / 1 month off. Use for anti-aging in your 50s+ (or earlier if mito labs show dysfunction) — young mice (human-20s/30s equivalent) saw no anti-aging benefit.
Use-case verdict
Top-tier for neurodegenerative disease/cognitive decline and TBI, close second chronic kidney disease; a role in insulin resistance/diabetes (but cheaper options exist first) and in chronic fatigue/long COVID (speculative). Less impressive in heart failure and macular degeneration (weak study effects). Great anti-aging add once mitochondria are dysfunctional.
Candidate notes reinforced
- Humanin (the other mitochondrial-derived peptide); CB4211 (MOTS-C analog) — both still candidates.